Immunocore Holdings plc
IMCRNASDAQHealthcare● Active
$27.79
$-0.50(-1.77%)
Market Cap$1.4B
P/E Ratio—
52W High$40.715
52W Low$27.555
Immunocore Holdings plc (IMCR) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
IMCR · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: May 6, 2026EPS Actual
$0.25
Est. -$0.26 · +196.2%
Revenue
$0.15B
Est. $0.15B · -0.3%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 6, 2026
After Market Close
▲ Beat EPS✓ 1-Quarter EPS Beat Streak
IMCR reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$0.21
Rev. $0.66B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$0.21
Rev. Est.$0.66B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 6, 2026 | -$0.01 | — | — | — | $0.15B | — |
| ▲ Q2 FY2026 | May 6, 2026 | -$0.26 | $0.25 | +196.2% | $0.15B | $0.15B | -0.3% |
| ▼ Q1 FY2026 | Feb 25, 2026 | -$0.28 | -$0.60 | -114.3% | $0.14B | $0.14B | -3.1% |
| ▲ Q4 FY2025 | Nov 6, 2025 | -$0.30 | $0.02 | +105.2% | $0.10B | $0.14B | -27.1% |
| ▲ Q3 FY2025 | Aug 7, 2025 | -$0.21 | -$0.20 | +4.8% | $0.13B | $0.13B | +0.1% |
| ▲ Q2 FY2025 | May 7, 2025 | -$0.35 | $0.10 | +128.6% | $0.12B | $0.12B | -0.3% |
| ▼ Q1 FY2025 | Feb 26, 2025 | -$0.31 | -$0.47 | -51.6% | $0.11B | $0.09B | +23.0% |
| ▲ Q4 FY2024 | Nov 6, 2024 | -$0.35 | $0.17 | +148.6% | $0.11B | $0.11B | -2.3% |
Q3 FY2026
Aug 6, 2026
EPS Actual
—
EPS Est.
-$0.01
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 6, 2026Beat
EPS Actual
$0.25
EPS Est.
-$0.26
EPS Surpr.
+196.2%
Revenue
$0.15B
Q1 FY2026
Feb 25, 2026Miss
EPS Actual
-$0.60
EPS Est.
-$0.28
EPS Surpr.
-114.3%
Revenue
$0.14B
Q4 FY2025
Nov 6, 2025Beat
EPS Actual
$0.02
EPS Est.
-$0.30
EPS Surpr.
+105.2%
Revenue
$0.10B
Q3 FY2025
Aug 7, 2025Beat
EPS Actual
-$0.20
EPS Est.
-$0.21
EPS Surpr.
+4.8%
Revenue
$0.13B
Q2 FY2025
May 7, 2025Beat
EPS Actual
$0.10
EPS Est.
-$0.35
EPS Surpr.
+128.6%
Revenue
$0.12B
Q1 FY2025
Feb 26, 2025Miss
EPS Actual
-$0.47
EPS Est.
-$0.31
EPS Surpr.
-51.6%
Revenue
$0.11B
Q4 FY2024
Nov 6, 2024Beat
EPS Actual
$0.17
EPS Est.
-$0.35
EPS Surpr.
+148.6%
Revenue
$0.11B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $0.09 | $0.09 | $0.10 | 2 |
| Q3 FY2027 | $0.04 | $0.05 | $0.05 | 2 |
| Q2 FY2027 | $-0.01 | $-0.01 | $-0.01 | 2 |
| Q1 FY2027 | $-0.03 | $-0.03 | $-0.03 | 3 |
| Q4 FY2026 | $-0.12 | $-0.12 | $-0.11 | 3 |
| Q3 FY2026 | $-0.16 | $-0.01 | $0.10 | 7 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $0.1B | $0.1B | $0.1B | 7 |
| Q3 FY2027 | $0.1B | $0.1B | $0.1B | 4 |
| Q2 FY2027 | $0.1B | $0.1B | $0.1B | 6 |
| Q1 FY2027 | $0.1B | $0.1B | $0.1B | 4 |
| Q4 FY2026 | $0.1B | $0.1B | $0.1B | 7 |
| Q3 FY2026 | $0.1B | $0.1B | $0.1B | 8 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q2 FY2026 | May 6, 2026 | +196.2% | $28.84 | $30.73 | +6.55% |
| ▼ Q1 FY2026 | Feb 25, 2026 | -114.3% | $33.68 | $32.16 | -4.51% |
| ▲ Q4 FY2025 | Nov 6, 2025 | +105.2% | $30.80 | $31.60 | +2.60% |
| ▲ Q3 FY2025 | Aug 7, 2025 | +4.8% | $32.10 | $31.93 | -0.53% |
| ▲ Q2 FY2025 | May 7, 2025 | +128.6% | $28.06 | $29.92 | +6.63% |
| ▼ Q1 FY2025 | Feb 26, 2025 | -51.6% | $29.21 | $30.77 | +5.34% |
| ▲ Q4 FY2024 | Nov 6, 2024 | +148.6% | $32.99 | $33.51 | +1.58% |
| ▲ Q3 FY2024 | Aug 8, 2024 | +48.9% | $36.90 | $37.92 | +2.76% |
Q2 FY2026+6.55%
Report Date
May 6, 2026
EPS Beat/Miss
+196.2%
Price Before
$28.84
Price After
$30.73
Q1 FY2026-4.51%
Report Date
Feb 25, 2026
EPS Beat/Miss
-114.3%
Price Before
$33.68
Price After
$32.16
Q4 FY2025+2.60%
Report Date
Nov 6, 2025
EPS Beat/Miss
+105.2%
Price Before
$30.80
Price After
$31.60
Q3 FY2025-0.53%
Report Date
Aug 7, 2025
EPS Beat/Miss
+4.8%
Price Before
$32.10
Price After
$31.93
Q2 FY2025+6.63%
Report Date
May 7, 2025
EPS Beat/Miss
+128.6%
Price Before
$28.06
Price After
$29.92
Q1 FY2025+5.34%
Report Date
Feb 26, 2025
EPS Beat/Miss
-51.6%
Price Before
$29.21
Price After
$30.77
Q4 FY2024+1.58%
Report Date
Nov 6, 2024
EPS Beat/Miss
+148.6%
Price Before
$32.99
Price After
$33.51
Q3 FY2024+2.76%
Report Date
Aug 8, 2024
EPS Beat/Miss
+48.9%
Price Before
$36.90
Price After
$37.92
Avg Beat Reaction+3.26%
Avg Miss Reaction+0.42%
Beat Rate6 / 8 quarters
Largest Move+6.63% (Q2 FY2025)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: IMCR ends December
Immunocore Holdings plc (IMCR) most recently reported earnings on May 6, 2026 for Q2 FY2026, posting EPS of $0.25 — beating the analyst consensus of $-0.26 by +196.2%. The next IMCR earnings date is expected around September 1, 2026.
Each quarter, investors track IMCR earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. IMCR revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
IMCR's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
IMCR earnings · 5 questionsImmunocore Holdings plc's next earnings report is expected around September 1, 2026. IMCR typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; IMCR historically reports after market close (AMC).
IMCR earnings datewhen is IMCR earningsIMCR next earnings datewhen does IMCR report earningsIMCR earnings calendar
▸ Source: FMP · Immunocore Holdings plc SEC filings · US GAAP · Immunocore Holdings plc SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026